StockData
Johnson & Johnson logo

Johnson & Johnson

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3042% above fair value
$270.56−2.64 (-0.97%)

Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%

Johnson & Johnson DARZALEX (daratumumab) — Worldwide sales by Quarter

DARZALEX (daratumumab) — Worldwide sales ($M) ($M)

QuarterlyAnnual

Johnson & Johnson DARZALEX (daratumumab) — Worldwide sales: $4,239M in Q3 2026, up 15.4% from a year earlier. That is the highest of the 40 quarters on record here.

Latest, Q3 2026
4,239
Period ended Sep 30, 2026
Change on a year earlier
+15.4%
3,672 in Q3 2025
History
40 quarters
Since Q4 2016
Sources
32
Documents cited below

Where the Q3 2026 figure comes from

Source: Form 10-Q (filed 2026-10-21) ↗

Reported in Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDARZALEX (daratumumab) — Worldwide sales ($M) ($M)Year on yearSource
Q3 2026Sep 30, 20264,239+15.4%Form 10-Q (filed 2026-10-21) ↗
Q2 2026Jun 28, 20264,207+18.9%Form 10-Q (filed 2026-07-23) ↗
Q1 2026Mar 29, 20263,964+22.5%Form 10-Q (filed 2026-04-22) ↗
Q4 2025Dec 28, 20253,903+26.6%Form 10-K (filed 2026-02-11) ↗
Q3 2025Sep 28, 20253,672+21.8%Form 10-Q (filed 2026-10-21) ↗
Q2 2025Jun 29, 20253,539+23.0%Form 10-Q (filed 2026-07-23) ↗
Q1 2025Mar 30, 20253,237+20.2%Form 10-Q (filed 2026-04-22) ↗
Q4 2024Dec 29, 20243,084+20.9%Form 10-K (filed 2026-02-11) ↗
Q3 2024Sep 29, 20243,016+20.7%Form 10-Q (filed 2025-10-22) ↗
Q2 2024Jun 30, 20242,878+18.4%Form 10-Q (filed 2025-07-24) ↗
Q1 2024Mar 31, 20242,692+18.9%Form 10-Q (filed 2025-04-23) ↗
Q4 2023Dec 31, 20232,550+22.4%Form 10-K (filed 2026-02-11) ↗
Q3 2023Oct 1, 20232,499+21.8%Form 10-Q (filed 2024-10-23) ↗
Q2 2023Jul 2, 20232,431+22.4%Form 10-Q (filed 2024-07-25) ↗
Q1 2023Apr 2, 20232,264+22.0%Form 10-Q (filed 2024-05-01) ↗
Q4 2022Jan 1, 20232,083+26.6%Form 10-K (filed 2025-02-13) ↗

Breakdown

What makes up DARZALEX (daratumumab) — Worldwide sales

Cite this data

StockData. (2026). Johnson & Johnson DARZALEX (daratumumab) — Worldwide sales ($M), quarterly Q4 2016–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-darzalex

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.